Compare Corning Incorporated (GLW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Regeneron Pharmaceuticals Inc — how do they compare? Corning Incorporated trades at $155.8 (market cap $150.10B), while Regeneron Pharmaceuticals Inc trades at $678.06 (market cap $69.66B). The key difference: Corning Incorporated is far larger — about 2.2× Regeneron Pharmaceuticals Inc's market cap, and Corning Incorporated pays the higher dividend (0.64%). Which is the better fit depends on your goals.
| GLW | REGN | |
|---|---|---|
Market Cap | $150.10B | $69.66B |
Sector | Technology | Health |
52-Week High | $255.79 | $812.27 |
52-Week Low | $52.97 | $542.52 |
Enterprise Value | $158.27B | $63.61B |
Dividend Yield | 0.64% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLW is trading at $156.59, down 16.57% over 24 hours, reflecting a significant pullback from recent highs. The stock shows bearish technical signals but maintains strong fundamentals with revenue growth to $15.63 billion in 2025 and net income of $1.60 billion. Recent earnings beats and analyst optimism around AI-driven optical communication demand provide a positive backdrop despite near-term volatility.
The outlook for GLW is cautiously optimistic, with a consensus price target of $210.10 implying substantial upside. Key opportunities include partnerships with NVIDIA and Amazon in AI infrastructure, while risks involve high valuation multiples and sensitivity to tech sector sentiment. Long-term growth in 5G and automotive glass supports the investment case.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
